Home › Targets › SSTR2
Radioligand therapy target profile

SSTR2: IHC Expression in Cancer and Radioligand Target Profile

somatostatin receptor 2 · Ensembl ENSG00000180616 · Data updated 2026-11-01
Also known as: Somatostatin receptor 2, SST2

SSTR2, somatostatin receptor 2, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, SSTR2 staining is highest in liver cancer (92% of samples positive), thyroid cancer (100% of samples positive) and neuroendocrine tumors (100% of samples positive). Published literature reports that SSTR2 internalizes after ligand binding, which helps retain a radionuclide inside tumor cells. Clinical status: FDA-approved radioligand therapy, with 1 active clinical trial.

177Lu-DOTATATE (Lutathera) is FDA-approved for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and SSTR2 is the receptor it targets.

Is SSTR2 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze SSTR2 free
LocalizationCell-Surface
Top cancer (IHC)Liver Cancer
InternalizationYes
Clinical stageFDA-approved radioligand therapy
Active trials1
Cancer association (Open Targets)0.66

Is SSTR2 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

SSTR2 IHC staining by cancer type

Protein expression of SSTR2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Liver Cancer0.56High92%
Thyroid Cancer0.50Medium100%
Neuroendocrine Tumors0.50Medium100%
Gastric Cancer0.50Medium83%
Colorectal Cancer0.47Medium92%
Bladder Cancer0.47Medium92%
Head and Neck Cancer0.42Medium75%
Skin Cancer0.42Medium67%
Melanoma0.39Medium75%
Endometrial Cancer0.33Medium73%
Cervical Cancer0.31Medium75%
Pancreatic Cancer0.31Medium58%
Glioma0.21Medium46%
Breast Cancer0.18Low55%
Lung Cancer0.17Low42%
Lymphoma0.14Low42%
Testicular Cancer0.11Low25%
Ovarian Cancer0.08Low25%
Prostate Cancer0.08Low17%
Kidney Cancer0.06Low18%

Is SSTR2 internalized?

Yes. This striking discordance unveils agonists' internalization trap-prolonged DOTANOC retention through SSTR2 endocytosis in estrogen-primed fibroids.

Sources: PMID 42149618 · PMID 41928014 · PMID 41900872 · PMID 41868663 · PMID 40883440. AI-extracted from abstracts, so verify before citing.

SSTR2 clinical trials

FDA-approved radioligand therapy. 1 active trial reference SSTR2 (ClinicalTrials.gov, accessed 2026-06-29).

NCT07178938

SSTR2 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SSTR2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

SSTR2 gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: -0.11 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related liver cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · HER2 (ERBB2) · Mesothelin (MSLN) · B7-H3 (CD276) · ITGAV

See all radioligand therapy targets in liver cancer.

See how SSTR2 ranks against 15,000 targets for your indication.

Analyze SSTR2 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is SSTR2 the right target for your program? · 5 free analyses, no card Analyze SSTR2 free